CVRx (NASDAQ:CVRX) is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.
The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure. CVRx has achieved regulatory milestones in key regions, having secured CE mark approval in Europe for both hypertension and heart failure indications. In parallel, the company is actively working with the U.S. Food and Drug Administration to advance its therapy through pivotal clinical data collection under the BeAT-HF (Barostim Therapy for Heart Failure) trial.
Founded in 2006 as a spin-out of Medtronic’s neuromodulation research program, CVRx established its headquarters in Minneapolis, Minnesota. Since its inception, the company has conducted international feasibility and pivotal studies, collaborating with leading cardiovascular centers in Europe, North America and Asia. CVRx began trading publicly on the NASDAQ under the ticker “CVRX” in 2018, positioning itself to leverage global partnerships and expand patient access to its technology.
CVRx is led by an executive team with deep expertise in medical device development, clinical research and regulatory strategy. The organization maintains commercial and clinical infrastructure across multiple geographies, with a focus on building physician and patient awareness of baroreflex activation therapy. Through ongoing innovation and evidence generation, CVRx aims to establish neuromodulation as a durable treatment option for cardiovascular patients worldwide.
